MARKET

CTLT

CTLT

Catalent Inc
NYSE
56.45
-0.03
-0.05%
After Hours: 56.33 -0.12 -0.21% 18:08 03/28 EDT
OPEN
56.48
PREV CLOSE
56.48
HIGH
56.76
LOW
56.38
VOLUME
1.84M
TURNOVER
0
52 WEEK HIGH
68.81
52 WEEK LOW
31.45
MARKET CAP
10.20B
P/E (TTM)
-7.8652
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CTLT last week (0318-0322)?
Weekly Report · 4d ago
Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Novo Nordisk announced plans to invest $556 million to expand its Tianjin production facility. BeiGene was approved to market a new drug in the US.
Seeking Alpha · 4d ago
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street
Congress is considering a bill to blacklist certain Chinese biotech companies. U.S. Companies have outsourced contract manufacturing and research to Chinese companies. The bill could have unintended consequences for companies that rely on those companies for drug development. Congress is considering the legislation to protect national-security concerns.
The Wall Street Journal · 5d ago
RSP, CTLT, CEG, ALGN: ETF Inflow Alert
NASDAQ · 03/20 16:18
Did Novo Nordisk Just Get a Jump on Eli Lilly?
The weight loss market is dominated by Eli Lilly and Novo Nordisk. Both companies have been testing their drugs as treatments for cardiovascular disease. The FDA recently approved Wegovy as a treatment to help prevent life-threatening cardiovascular events in people with diabetes and obesity. The market for heart disease treatments is expected to exceed $200 billion annually.
The Motley Fool · 03/19 11:30
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
NASDAQ · 03/18 10:20
Weekly Report: what happened at CTLT last week (0311-0315)?
Weekly Report · 03/18 09:07
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, EVBG, ZFOX
Halper Sadeh LLC is investigating the following companies for potential violations of the federal securities laws. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. The firm may seek increased consideration for shareholders and other relief and benefits on behalf of shareholders. Catalent, Inc. And Everbridge are being investigated.
PR Newswire · 03/12 15:50
More
About CTLT
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

Webull offers Catalent Inc stock information, including NYSE: CTLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTLT stock methods without spending real money on the virtual paper trading platform.